Dr Kleenz Laboratories Profile
Key Indicators
- Authorised Capital ₹ 2.00 M
as on 19-12-2024
- Paid Up Capital ₹ 1.95 M
as on 19-12-2024
- Company Age 15 Year, 10 Days
- Last Filing with ROC 31 Mar 2024
- Revenue 47.83%
(FY 2020)
- Profit -112.83%
(FY 2020)
- Ebitda -46.47%
(FY 2020)
- Net Worth -0.87%
(FY 2020)
- Total Assets 41.75%
(FY 2020)
About Dr Kleenz Laboratories
The Company is engaged in the Fmcg Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 2.00 M and a paid-up capital of Rs 1.95 M, as per Ministry of Corporate Affairs (MCA) records.
Monika Gupta and Jagmohan Bijalwan serve as directors at the Company.
- CIN/LLPIN
U74120DL2009PTC196967
- Company No.
196967
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
15 Dec 2009
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
Delhi, India
- Telephone
- Email Address
- Website
- Social Media
What products or services does Dr Kleenz Laboratories Private Limited offer?
Dr Kleenz Laboratories Private Limited offers a wide range of products and services, including Toothpastes, Meswak Toothpaste, Hair Comb, Dabur Toothpaste, Occasional Gift, Diwali Gifts, Hand Sanitizer & Disinfectant, Alcohol Based Hand Sanitizer, Hand Sanitizers & Personal Hygiene, Hand Wash.
Who are the key members and board of directors at Dr Kleenz Laboratories?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Monika Gupta  | Director | 15-Dec-2009 | Current |
| Jagmohan Bijalwan | Director | 15-Dec-2009 | Current |
Financial Performance of Dr Kleenz Laboratories.
Dr Kleenz Laboratories Private Limited, for the financial year ended 2020, experienced significant growth in revenue, with a 47.83% increase. The company also saw a substantial fall in profitability, with a 112.83% decrease in profit. The company's net worth dipped by a decrease of 0.87%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Dr Kleenz Laboratories?
In 2020, Dr Kleenz Laboratories had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Onyx Interiors Private LimitedActive 11 years 13 daysMonika Gupta and Jagmohan Bijalwan are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Dr Kleenz Laboratories?
Unlock and access historical data on people associated with Dr Kleenz Laboratories, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Dr Kleenz Laboratories, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Dr Kleenz Laboratories's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
